Maximizers: The Quieter, More Expensive Threat to Your Copay Program

Accumulators get most of the airtime in the manufacturer copay conversation. Maximizers, in 2026, are the more expensive design.

Industry analysts, including Drug Channels Institute, consistently flag maximizer adoption as the faster-growing of the two designs, and the more economically punishing for manufacturers per affected patient. The mechanism is more subtle than an accumulator, the design is harder to identify from claims data, and a meaningful percentage of every dollar that flows through the maximizer is captured by the maximizer vendor as a fee.

Here is how the design works, why it has been growing faster than accumulators, and what manufacturers are doing about it now.

The maximizer design, in plain English

A copay maximizer takes a different path than an accumulator. The plan classifies the drug as a "non-essential health benefit," which removes the cap on patient out-of-pocket spend. The plan then sets the patient's cost-share at a level calibrated against the manufacturer's full annual copay benefit — not at typical commercial cost-sharing levels.

What this means mechanically: the manufacturer's annual copay program for that patient is engineered to run out across the plan year, with the maximizer vendor capturing a percentage of the total disbursement as their fee. Industry estimates put that fee at 25%+ of program value.

The patient is technically held harmless during the period the maximizer is paying. The manufacturer's program runs through its annual benefit at the maximizer's pace. The plan saves money on what the cost-share would have otherwise been. The maximizer vendor gets paid.

When the year resets, the design resets with it. There is no permanent fix at the patient level.

Why maximizers have been growing faster than accumulators

Three reasons.

1. Accumulators have attracted state-level legislative attention. As of 2026, more than half of U.S. states have enacted some form of copay accumulator adjustment legislation, requiring fully insured plans to count manufacturer assistance toward the deductible. Maximizers, classified as non-essential-health-benefit designs, sit in a different regulatory bucket and have largely escaped the state-level constraints applied to accumulators.

2. The economics for the plan are stronger. An accumulator captures the deductible value once per patient per plan year. A maximizer captures the entire engineered annual copay benefit, every plan year, repeatedly.

3. Vendor incentives. Maximizer vendors are paid a percentage of program value captured. Their growth is a direct function of how aggressively they recruit plan sponsors into the design. It is, structurally, a high-margin business model with a built-in growth motor.

Net result: the manufacturers we work with are seeing maximizer exposure grow as a share of total copay program diversion, year over year.

Why maximizer detection is harder than accumulator detection

Accumulators leave a relatively visible signal in claims data: the patient's deductible balance does not move while assistance is paying. Pattern recognition gets you most of the way there.

Maximizers are harder. The "non-essential health benefit" classification is a plan-design choice that doesn't always surface clearly in claim adjudication data. The patient's effective cost-share at the point of sale looks consistent across the year, even though the underlying mechanic is engineered against the manufacturer's program. Many maximizer designs only become visible in retrospect — after a quarter or two of disbursement data accumulates.

That detection lag is exactly the design feature that makes maximizers valuable to plan sponsors and maximizer vendors. By the time the manufacturer can confirm the design and adjust program rules, the year's program disbursement is largely captured.

The shift to in-claim segmentation

The same shift that's been happening in accumulator defense is happening, more slowly, in maximizer defense: from retrospective detection toward real-time segmentation at the point of sale.

The technical bar is higher for maximizers. Accumulator signals can often be inferred from a single claim. Maximizer signals require correlating plan-design metadata, patient cost-share patterns, and benefit-classification flags across multiple claims and multiple data sources. Doing this in real time, at point-of-sale latency, is non-trivial.

But the manufacturers we work with are increasingly unwilling to accept quarterly maximizer reports as a defense posture. They want exposure identified at first fill, segmented with high accuracy, and the manufacturer's contribution adjusted before the design captures the full annual program.

The bottom line

Maximizers are the more economically punishing design per affected patient, the faster-growing design year over year, and the more difficult design to detect in standard claims data.

Manufacturers running specialty brands in 2026 should treat maximizer defense as a separate, higher-priority capability than accumulator defense — not as a subset of it. The infrastructure required is more demanding. The economic exposure per patient is larger. And the regulatory horizon is longer.

The manufacturers whose specialty programs survive this design intact will be the ones who treat maximizer defense as a real-time capability owned end to end, not a quarterly retrospective.

Want to see what your specific program's maximizer exposure looks like? We can model it against your current program data, with no migration required. Request an exposure review.